デフォルト表紙
市場調査レポート
商品コード
1579714

SNPジェノタイピングと分析の世界市場

SNP Genotyping and Analysis

出版日
ページ情報
英文 173 Pages
納期
即日から翌営業日
適宜更新あり
SNPジェノタイピングと分析の世界市場
出版日: 2024年10月30日
発行: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
ページ情報: 英文 173 Pages
納期: 即日から翌営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

SNPジェノタイピングと分析の世界市場は2030年までに591億米ドルに到達

2023年に178億米ドルと推定されたSNPジェノタイピングと分析の世界市場は、2030年には591億米ドルに達し、分析期間2023-2030年のCAGRは18.7%で成長すると予測されます。本レポートで分析したセグメントの1つであるマイクロアレイとジーンチップによるSNPジェノタイピングは、CAGR 22.2％を記録し、分析期間終了までに229億米ドルに達すると予測されます。Taqman Allelic Discrimination セグメントの成長率は、分析期間中CAGR 17.9%と推定されます。

米国市場は51億米ドルと推定、中国はCAGR18.0%で成長予測

米国のSNPジェノタイピングと分析市場は2023年に51億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに90億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは18.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ16.9%と15.1%と予測されています。欧州では、ドイツがCAGR約12.3%で成長すると予測されています。

世界のSNPジェノタイピングと分析市場- 主要動向と促進要因まとめ

SNPジェノタイピングと分析とは何か、なぜゲノム研究とプレシジョン医療の推進に不可欠なのか？

SNPジェノタイピングと分析とは、一塩基多型（SNP）-ゲノムの特定の位置で生じる一塩基の変異-を同定し調べるプロセスを指します。これらの遺伝子変異は、病気や薬、環境要因に対する個人の反応に影響を与える重要なマーカーです。SNPを分析することにより、研究者は遺伝的変異と特定の形質や状態との関連を明らかにすることができ、遺伝的素因や様々な疾患の根底にある分子メカニズムについての洞察を得ることができます。SNPジェノタイピングは、ゲノム研究、ファーマコゲノミクス、農業バイオテクノロジー、精密医療などの多様な分野で広く利用されており、遺伝的変異を理解することで、標的療法の開発、個別化治療計画、作物や家畜の品種改良につながります。

SNPジェノタイピングと分析の世界の普及は、複雑な形質や疾病に関連する遺伝的変異をより正確かつ効率的に同定することを可能にし、遺伝子研究やヘルスケアの分野に変革をもたらしつつあります。SNPは、ヒトゲノムの中で最も一般的な遺伝的変異であり、その解析は、遺伝的多様性と生物学的機能への影響を研究するための費用対効果に優れたハイスループットな手段を提供します。ヘルスケアでは、SNPジェノタイピングは、臨床医が薬剤に対する個人の反応を予測し、疾患の危険因子を特定し、遺伝子プロファイルに基づいて治療を調整することを可能にすることで、精密医療において極めて重要な役割を果たしています。疾患関連研究におけるSNPジェノタイピングの利用は、がん、糖尿病、心血管疾患、神経疾患などの疾患の遺伝的危険因子の同定につながっています。個別化医療とゲノム研究の需要が高まり続ける中、SNPジェノタイピングと分析は、人間の健康と病気についての理解を深めるために不可欠なツールになりつつあります。

技術の進歩は、SNPジェノタイピングと分析の開発と応用をどのように形成していますか？

技術の進歩は、SNPジェノタイピングと分析の効率性、正確性、適用範囲を大幅に向上させ、研究者や臨床医が遺伝的変異とそれが健康や病気に与える影響についてより深い洞察を得ることを可能にしています。この分野における最も重要な技術革新の一つは、マイクロアレイや次世代シーケンシング（NGS）技術などのハイスループット遺伝子型解析プラットフォームの開発です。マイクロアレイは、研究者が数千のSNPを同時に解析することを可能にし、遺伝子変異と表現型形質との相関を大規模に同定するゲノムワイド関連研究（GWAS）を実施することを可能にします。マイクロアレイ技術は、その費用対効果、スピード、高品質なデータを提供する能力により、ジェノタイピングの標準的なツールとなっています。さらに、NGS技術の進歩により、研究者はゲノム全体または標的領域の配列を比類のない深さと精度で決定できるようになり、従来のジェノタイピング法では捉えられなかった希少SNPや構造的バリアントの検出が可能になっています。

もう一つの主な技術的発展は、バイオインフォマティクスとデータ解析ツールの統合です。これらは、SNPジェノタイピングとシーケンスによって生成される膨大な量のデータを処理し、解釈するために不可欠です。バイオインフォマティクスのソフトウェアやアルゴリズムは、SNPを同定し、その機能的効果を予測し、疾患や形質との関連を評価するために使用されています。これらのツールにより、研究者は複雑な統計解析を行い、遺伝子データを可視化し、遺伝子発現やエピジェネティック修飾などの複数のデータを統合して、生物学的プロセスに対する遺伝的影響の全体的な理解を得ることができます。また、機械学習やAIもSNP解析に応用され、遺伝データに基づくパターンの同定や予後の予測に利用され、バイオマーカーや治療標的の発見に新たな機会を提供しています。

さらに、シングルセル・ジェノタイピングとデジタルPCR（dPCR）の進歩により、SNP解析の応用範囲は、がん研究、生殖医療、発生生物学などの分野にも広がっています。シングルセル・ジェノタイピングにより、研究者は個々の細胞レベルでの遺伝的変異を解析することができ、複雑な組織や腫瘍における細胞の不均一性やクローン進化に関する洞察を得ることができます。この技術は腫瘍学において特に価値が高く、腫瘍内の遺伝的多様性を理解することで、治療戦略に情報を与え、患者の転帰を改善することができます。同様に、dPCRは低頻度のSNPやコピー数の変異を高い感度と特異性で検出できるため、リキッドバイオプシー、出生前検査、病原体の検出などのアプリケーションに理想的です。このような技術的進歩は、NPジェノタイピングと分析の能力を向上させるだけでなく、その応用範囲を広げ、研究および臨床応用の両方において汎用性の高いツールとなっています。

様々なセクターや地域でSNPジェノタイピングと分析の採用を促進している要因は何ですか？

SNPジェノタイピングと分析の採用は、遺伝性疾患の有病率の増加、個別化医療への需要の高まり、農業バイオテクノロジーへの注目の高まりなど、いくつかの重要な要因によって推進されています。主要な促進要因の一つは、遺伝性疾患の有病率の増加と、診断および治療ソリューションの改善に対するニーズです。疾患の遺伝的基盤に関する理解が拡大するにつれ、疾患感受性や薬剤反応性に寄与する遺伝的変異を正確かつ効率的に検出する方法の必要性が高まっています。SNPジェノタイピングは、これらの変異を同定するための貴重なツールを提供し、研究者や臨床医がより効果的な診断検査や治療戦略を開発することを可能にします。この動向は特に腫瘍学において顕著であり、SNP解析はがんに関連する変異の同定、治療方針の決定、疾患の進行のモニタリングに利用されています。

SNPジェノタイピングの採用を促進するもう一つの重要な要因は、個別化医療に対する需要の高まりです。精密医療は、遺伝的、環境的、ライフスタイル的要因に基づいて個々の患者に合わせた治療を行うことを目的としています。SNPジェノタイピングは、遺伝的変異が薬物代謝、有効性、安全性にどのように影響するかについての洞察を提供することにより、このアプローチにおいて重要な役割を果たしています。個別化医療の重要な要素であるファーマコゲノミクスでは、SNP解析を用いて薬物反応に影響する遺伝子マーカーを同定し、臨床医が患者ごとに最も適切な治療法と投与量を選択できるようにします。この個別化されたアプローチは、治療結果を改善するだけでなく、薬物有害反応のリスクを低減し、患者の安全性と満足度を高める。ファーマコゲノミクスにおけるSNPジェノタイピングの利用の増加は、特に北米や欧州のような精密医療への取り組みが活発化している先進地域のヘルスケア現場での採用を促進しています。

さらに、農業バイオテクノロジーへの注目の高まりが、作物や家畜の育種におけるSNPジェノタイピングの採用に影響を与えています。農業では、SNP分析は、耐病性、干ばつ耐性、高収量などの望ましい形質に関連する遺伝マーカーを同定するために使用されます。これらのマーカーを選抜することで、育種家は環境条件の変化や市場の需要により適した改良作物品種や家畜品種を開発することができます。SNPジェノタイピングはまた、植物や動物のゲノム研究においても重要な役割を果たしており、遺伝子のマッピング、遺伝的多様性の研究、複雑な形質の遺伝的基盤の理解に利用されています。この技術は、特にアジア太平洋やラテンアメリカなど、農業が経済の重要な構成要素となっている地域において、持続可能な農業慣行の開発を加速し、食糧安全保障を改善するのに役立っています。このような要因が遺伝子研究や精密育種に対する需要を形成し続けているため、SNPジェノタイピングの採用はさまざまな分野や地域で拡大すると予想されます。

世界のSNPジェノタイピングと分析市場の成長を牽引しているのは？

世界のSNPジェノタイピングと分析市場の成長は、ゲノム研究への投資の増加、遺伝性疾患の発生率の上昇、ジェノタイピング技術の進歩など、いくつかの要因によってもたらされます。主な成長要因の1つは、政府、学術機関、非公開会社によるゲノム研究への投資の増加です。ヒトの健康と疾病を理解する上でゲノム研究の重要性が高まり続ける中、遺伝的変異のマッピング、疾病関連SNPの同定、新規治療法の開発を目的としたプロジェクトやイニシアチブへの資金提供への注目が高まっています。ヒトゲノムプロジェクト、1000ゲノムプロジェクト、UKバイオバンクのような主要なイニシアチブは、膨大な量の遺伝子データを生み出し、さらなる研究の基盤を提供し、先進的なSNPジェノタイピングと分析ツールの需要を促進しています。ゲノミクス研究への資金提供の可能性が高まっていることから、特に大規模なゲノム研究が行われている北米や欧州などの先進地域において、市場拡大の機会が生まれています。

市場成長のもう一つの重要な促進要因は、遺伝性疾患の罹患率の上昇と診断・治療ソリューションの改善ニーズです。嚢胞性線維症、鎌状赤血球貧血、ハンチントン病などの遺伝性疾患は、SNPジェノタイピングによって特定できる特定の遺伝子変異によって引き起こされることが多いです。これらの疾患に対する認識が高まり、診断技術が向上するにつれ、正確で早期診断が可能な遺伝子検査サービスへの需要が高まっています。SNPジェノタイピングは、遺伝子変異を同定し疾患リスクを評価するための信頼性の高い方法を提供し、臨床現場での採用を後押ししています。遺伝性疾患の有病率の増加は、特にアジア太平洋や中東などの地域で顕著であり、遺伝子検査や個別化医療に対する需要が急速に高まっています。

さらに、ジェノタイピング技術の進歩がSNPジェノタイピングと分析市場の成長を支えています。NGSやマイクロアレイなどのハイスループットプラットフォームの開発により、研究者は大規模なジェノタイピング研究を低コストかつ高精度で実施できるようになっています。また、これらの技術は、複数のSNPの累積効果に基づいて一般的な疾患に対する個人の遺伝的リスクを評価する多遺伝子リスクスコアなど、SNP解析の新しいアプリケーションの開発にも利用されています。ハイスループット・ジェノタイピングや複雑な遺伝子データの解析が可能になったことで、SNPジェノタイピングの適用範囲が従来の用途を超えて拡大し、研究や臨床での新たな利用機会が生まれています。さらに、市販のジェノタイピングサービスや消費者直販の遺伝子検査キットの利用が可能になりつつあることで、SNP解析がより多くの人々にとって身近なものとなり、市場の成長をさらに後押ししています。

さらに、精密医療が重視されるようになり、ゲノムデータの臨床への統合が進んでいることも、SNPジェノタイピングと分析市場の成長に影響を与えています。米国のプレシジョン・メディシン・イニシアチブ（Precision Medicine Initiative）や欧州の100万人超ゲノム・イニシアチブ（European 1+million Genomes Initiative）などのプレシジョン・メディシン・イニシアチブは、臨床上の意思決定に情報を提供し、患者の転帰を改善するための遺伝子データの利用を推進しています。これらのイニシアチブはヘルスケアの現場におけるSNPジェノタイピングの採用を促進し、治療方針の決定、疾病リスクの予測、潜在的な創薬標的の同定に利用されています。このような要因が世界のゲノミクス情勢を形成し続ける中、市場情勢は、研究投資の増加、技術の進歩、個別化医療や遺伝子検査ソリューションの需要増に牽引され、力強い成長が見込まれています。

調査対象企業の例（注目の42社）

  • Affymetrix, Inc.
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Life Technologies Corporation
  • Sequenom, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP16798

Global SNP Genotyping and Analysis Market to Reach US$59.1 Billion by 2030

The global market for SNP Genotyping and Analysis estimated at US$17.8 Billion in the year 2023, is expected to reach US$59.1 Billion by 2030, growing at a CAGR of 18.7% over the analysis period 2023-2030. SNP Genotyping by Microarrays and GeneChips, one of the segments analyzed in the report, is expected to record a 22.2% CAGR and reach US$22.9 Billion by the end of the analysis period. Growth in the Taqman Allelic Discrimination segment is estimated at 17.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 18.0% CAGR

The SNP Genotyping and Analysis market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.0 Billion by the year 2030 trailing a CAGR of 18.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.9% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.3% CAGR.

Global SNP Genotyping and Analysis Market - Key Trends & Drivers Summarized

What Is SNP Genotyping and Analysis and Why Is It Crucial for Advancing Genomic Research and Precision Medicine?

SNP genotyping and analysis refers to the process of identifying and examining single nucleotide polymorphisms (SNPs)—variations in a single nucleotide that occur at a specific position in the genome. These genetic variations are crucial markers that can influence how individuals respond to diseases, medications, and environmental factors. By analyzing SNPs, researchers can uncover associations between genetic variations and specific traits or conditions, providing insights into genetic predispositions and the molecular mechanisms underlying various diseases. SNP genotyping is widely used in diverse fields such as genomic research, pharmacogenomics, agricultural biotechnology, and precision medicine, where understanding genetic variation can lead to the development of targeted therapies, personalized treatment plans, and improved crop and livestock breeding.

The global adoption of SNP genotyping and analysis is transforming the fields of genetic research and healthcare by enabling more accurate and efficient identification of genetic variants associated with complex traits and diseases. SNPs are the most common type of genetic variation in the human genome, and their analysis provides a cost-effective and high-throughput means of studying genetic diversity and its effects on biological functions. In healthcare, SNP genotyping plays a pivotal role in precision medicine by allowing clinicians to predict individual responses to drugs, identify risk factors for diseases, and tailor treatments based on genetic profiles. The use of SNP genotyping in disease association studies has led to the identification of genetic risk factors for conditions such as cancer, diabetes, cardiovascular diseases, and neurological disorders. As the demand for personalized medicine and genomic research continues to grow, SNP genotyping and analysis are becoming essential tools for advancing our understanding of human health and disease.

How Are Technological Advancements Shaping the Development and Application of SNP Genotyping and Analysis?

Technological advancements are significantly enhancing the efficiency, accuracy, and scope of SNP genotyping and analysis, enabling researchers and clinicians to gain deeper insights into genetic variations and their impact on health and disease. One of the most significant innovations in this field is the development of high-throughput genotyping platforms, such as microarrays and next-generation sequencing (NGS) technologies. Microarrays allow researchers to analyze thousands of SNPs simultaneously, making it possible to conduct genome-wide association studies (GWAS) that identify correlations between genetic variants and phenotypic traits on a large scale. Microarray technology has become a standard tool for genotyping due to its cost-effectiveness, speed, and ability to provide high-quality data. Additionally, advances in NGS technology are enabling researchers to sequence entire genomes or targeted regions with unparalleled depth and accuracy, allowing for the detection of rare SNPs and structural variants that are not captured by traditional genotyping methods.

Another key technological development is the integration of bioinformatics and data analysis tools, which are essential for processing and interpreting the vast amounts of data generated by SNP genotyping and sequencing. Bioinformatics software and algorithms are being used to identify SNPs, predict their functional effects, and assess their association with diseases or traits. These tools enable researchers to perform complex statistical analyses, visualize genetic data, and integrate multiple data types, such as gene expression and epigenetic modifications, to gain a holistic understanding of genetic influences on biological processes. Machine learning and AI are also being applied to SNP analysis to identify patterns and predict outcomes based on genetic data, providing new opportunities for discovering biomarkers and therapeutic targets.

Furthermore, advancements in single-cell genotyping and digital PCR (dPCR) are expanding the applications of SNP analysis to areas such as cancer research, reproductive health, and developmental biology. Single-cell genotyping allows researchers to analyze genetic variations at the level of individual cells, providing insights into cellular heterogeneity and clonal evolution in complex tissues or tumors. This technology is particularly valuable in oncology, where understanding the genetic diversity within a tumor can inform treatment strategies and improve patient outcomes. Similarly, dPCR offers high sensitivity and specificity for detecting low-frequency SNPs and copy number variations, making it ideal for applications such as liquid biopsy, prenatal testing, and pathogen detection. These technological advancements are not only enhancing the capabilities of SNP genotyping and analysis but are also broadening its application scope, making it a versatile tool for both research and clinical applications.

What Factors Are Driving the Adoption of SNP Genotyping and Analysis Across Various Sectors and Regions?

The adoption of SNP genotyping and analysis is being driven by several key factors, including the increasing prevalence of genetic diseases, the growing demand for personalized medicine, and the rising focus on agricultural biotechnology. One of the primary drivers is the increasing prevalence of genetic diseases and the need for improved diagnostic and therapeutic solutions. As our understanding of the genetic basis of diseases continues to expand, there is a growing need for accurate and efficient methods of detecting genetic variations that contribute to disease susceptibility or drug response. SNP genotyping provides a valuable tool for identifying these variations, enabling researchers and clinicians to develop more effective diagnostic tests and therapeutic strategies. This trend is particularly strong in oncology, where SNP analysis is used to identify cancer-associated mutations, guide treatment decisions, and monitor disease progression.

Another significant factor driving the adoption of SNP genotyping is the growing demand for personalized medicine. Precision medicine aims to tailor treatments to individual patients based on their genetic, environmental, and lifestyle factors. SNP genotyping plays a critical role in this approach by providing insights into how genetic variations affect drug metabolism, efficacy, and safety. Pharmacogenomics, a key component of personalized medicine, uses SNP analysis to identify genetic markers that influence drug response, enabling clinicians to select the most appropriate treatment and dosage for each patient. This personalized approach not only improves treatment outcomes but also reduces the risk of adverse drug reactions, enhancing patient safety and satisfaction. The increasing use of SNP genotyping in pharmacogenomics is driving its adoption in healthcare settings, particularly in developed regions such as North America and Europe, where precision medicine initiatives are gaining momentum.

Moreover, the rising focus on agricultural biotechnology is influencing the adoption of SNP genotyping in crop and livestock breeding. In agriculture, SNP analysis is used to identify genetic markers associated with desirable traits such as disease resistance, drought tolerance, and high yield. By selecting for these markers, breeders can develop improved crop varieties and livestock breeds that are better suited to changing environmental conditions and market demands. SNP genotyping also plays a key role in plant and animal genomics research, where it is used to map genes, study genetic diversity, and understand the genetic basis of complex traits. This technology is helping to accelerate the development of sustainable agricultural practices and improve food security, particularly in regions such as Asia-Pacific and Latin America, where agriculture is a critical component of the economy. As these factors continue to shape the demand for genetic research and precision breeding, the adoption of SNP genotyping is expected to expand across various sectors and regions.

What Is Driving the Growth of the Global SNP Genotyping and Analysis Market?

The growth in the global SNP Genotyping and Analysis market is driven by several factors, including the increasing investment in genomic research, the rising incidence of genetic disorders, and advancements in genotyping technologies. One of the primary growth drivers is the increasing investment in genomic research by governments, academic institutions, and private companies. As the importance of genomics in understanding human health and disease continues to grow, there is a rising focus on funding projects and initiatives that aim to map genetic variations, identify disease-associated SNPs, and develop novel therapies. Major initiatives such as the Human Genome Project, the 1000 Genomes Project, and the UK Biobank have generated vast amounts of genetic data, providing a foundation for further research and driving the demand for advanced SNP genotyping and analysis tools. The growing availability of funding for genomics research is creating opportunities for market expansion, particularly in developed regions such as North America and Europe, where large-scale genomic studies are underway.

Another significant driver of market growth is the rising incidence of genetic disorders and the need for improved diagnostic and therapeutic solutions. Genetic disorders, such as cystic fibrosis, sickle cell anemia, and Huntington’s disease, are often caused by specific genetic variations that can be identified through SNP genotyping. As awareness of these conditions increases and diagnostic technologies improve, there is a growing demand for genetic testing services that can provide accurate and early diagnosis. SNP genotyping offers a reliable method for identifying genetic mutations and assessing disease risk, supporting its adoption in clinical settings. The increasing prevalence of genetic disorders is particularly pronounced in regions such as Asia-Pacific and the Middle East, where the demand for genetic testing and personalized medicine is growing rapidly.

Moreover, advancements in genotyping technologies are supporting the growth of the SNP genotyping and analysis market. The development of high-throughput platforms, such as NGS and microarrays, is enabling researchers to conduct large-scale genotyping studies at a lower cost and with higher accuracy. These technologies are also being used to develop new applications for SNP analysis, such as polygenic risk scores, which assess an individual’s genetic risk for common diseases based on the cumulative effect of multiple SNPs. The ability to perform high-throughput genotyping and analyze complex genetic data is expanding the scope of SNP genotyping beyond traditional applications, creating new opportunities for research and clinical use. Additionally, the increasing availability of commercial genotyping services and direct-to-consumer genetic testing kits is making SNP analysis more accessible to a wider audience, further driving market growth.

Furthermore, the growing emphasis on precision medicine and the integration of genomic data into clinical practice are influencing the growth of the SNP genotyping and analysis market. Precision medicine initiatives, such as the U.S. Precision Medicine Initiative and the European 1+ Million Genomes Initiative, are promoting the use of genetic data to inform clinical decision-making and improve patient outcomes. These initiatives are driving the adoption of SNP genotyping in healthcare settings, where it is used to guide treatment decisions, predict disease risk, and identify potential drug targets. As these factors continue to shape the global genomics landscape, the SNP Genotyping and Analysis market is expected to experience robust growth, driven by rising investment in research, technological advancements, and the increasing demand for personalized medicine and genetic testing solutions.

Select Competitors (Total 42 Featured) -

  • Affymetrix, Inc.
  • F. Hoffmann-La Roche AG
  • Fluidigm Corporation
  • Illumina, Inc.
  • Life Technologies Corporation
  • Sequenom, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • SNP Genotyping and Analysis - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Personalized Medicine Spurs Growth of SNP Genotyping and Analysis Market
    • Increased Use of SNP Genotyping in Disease Risk Assessment Expands Addressable Market
    • Focus on Enhancing Drug Development and Clinical Trials Fuels Market Demand for SNP Analysis
    • Rising Adoption of SNP Genotyping in Agricultural and Livestock Research Supports Market Expansion
    • Growing Use of SNP Analysis in Pharmacogenomics Strengthens Business Case for Market Growth
    • Rising Use of SNP Genotyping for Ancestry and Genetic Heritage Testing Fuels Market Demand
    • Increased Adoption of Next-Generation Sequencing (NGS) in SNP Genotyping Propels Market Growth
    • Rising Demand for SNP Genotyping in Population Genomics and Epidemiology Studies Supports Market Growth
    • Growing Use of SNP Genotyping in Oncology and Cancer Research Fuels Market Growth
    • Rising Use of SNP Genotyping in Animal Breeding and Conservation Genetics Sets the Stage for Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World SNP Genotyping and Analysis Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for SNP Genotyping and Analysis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for SNP Genotyping and Analysis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for SNP Genotyping by Microarrays and GeneChips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for SNP Genotyping by Microarrays and GeneChips by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for SNP Genotyping by Microarrays and GeneChips by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Taqman Allelic Discrimination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Taqman Allelic Discrimination by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Taqman Allelic Discrimination by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for SNP Pyrosequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for SNP Pyrosequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for SNP Pyrosequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Applied Biosciences SNPlex by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Applied Biosciences SNPlex by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Applied Biosciences SNPlex by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Sequenom MassARRAY MALDI-TOF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Sequenom MassARRAY MALDI-TOF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Sequenom MassARRAY MALDI-TOF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Diagnostic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Diagnostic Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Diagnostic Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Pharmaceuticals and Pharmacogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Pharmaceuticals and Pharmacogenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Pharmaceuticals and Pharmacogenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Agricultural Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Agricultural Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Agricultural Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Breeding and Animal Livestock by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Breeding and Animal Livestock by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Breeding and Animal Livestock by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Canada 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • JAPAN
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • CHINA
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • EUROPE
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for SNP Genotyping and Analysis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for SNP Genotyping and Analysis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • FRANCE
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: France Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: France 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • GERMANY
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Germany 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Italy 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: UK 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • SNP Genotyping and Analysis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for SNP Genotyping and Analysis by Technology - SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for SNP Genotyping and Analysis by Technology - Percentage Breakdown of Value Sales for SNP Genotyping by Microarrays and GeneChips, Taqman Allelic Discrimination, SNP Pyrosequencing, Applied Biosciences SNPlex and Sequenom MassARRAY MALDI-TOF for the Years 2014, 2024 & 2030
    • TABLE 104: Rest of World Recent Past, Current & Future Analysis for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Rest of World Historic Review for SNP Genotyping and Analysis by Application - Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Rest of World 16-Year Perspective for SNP Genotyping and Analysis by Application - Percentage Breakdown of Value Sales for Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology and Breeding and Animal Livestock for the Years 2014, 2024 & 2030

IV. COMPETITION